Triple-Drug cocktail aims to tame untreated CLL

NCT ID NCT07674810

Not yet recruiting Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether a combination of three drugs—zanubrutinib, sonrotoclax, and obinutuzumab—can safely control chronic lymphocytic leukemia (CLL) in people who have not yet received treatment. About 40 participants will receive all three drugs orally. The main goal is to check for side effects and see how well the body tolerates the combination.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zanubrutinib, sonrotoclax, and obinutuzumab
What this could lead to: If successful, this three-drug combination could offer a powerful new option to control CLL without prior treatment, potentially improving long-term outcomes.
What could go wrong: This is a small, early-phase trial (40 people) focused on safety. The combination may cause side effects, and it is not yet known if it works better than existing therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA

Contacts and locations

Locations

UT MD Anderson

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.